STTR Phase I: Novel Molecularly Targeted Tracer for Specific and Sensitive Imaging of Cancer

STTR 第一阶段：用于癌症特异性和灵敏成像的新型分子靶向示踪剂

• 批准号: 1321424
• 负责人: Anka Veleva
• 金额: $ 22.5万
• 依托单位: Clave Biodesign, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-01 至 2014-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1321424&HistoricalAwards=false
• 关键词: STTR; Phase; Novel; Molecularly; Targeted

This Small Business Technology Transfer Phase I project takes an innovative approach at tumor targeting by investigating an entirely novel tumor targeting platform that utilizes bone marrow derived, circulating tumor homing cells as natural vectors. Through screening of phage display peptide libraries we have identified high affinity peptide ligands that bind these cells with high specificity. These high affinity, high specificity peptide ligands and their applications for molecular imaging of tumor?s blood supply represent the innovation in this Phase I project. Radiolabeled peptide directed compounds will be synthersized and their potential to deliver molecular ?payloads? specifically to malignant vasculature in a mouse model of cancer will be characterized. The results from this development effort will provide proof-of-principle validation for a new targeting paradigm in which circulating tumor localizing cell populations can be exploited for highly transformative and innovative technology development for the benefit of cancer patients.The broader impact of this project and the commercialization of the molecular diagnostic tracer developed here will have important implications for furthering oncology care through personalized approaches: First, specific and sensitive imaging based on monitoring of homing of circulating cells to tumor tissue will be beneficial for tumor staging and re-staging. Second, in addition the outcomes of this development effort would provide more predictable information relevant to treatment that has been lacking so far. Close assessment of patient?s response to treatment by monitoring the presence or absence of circulating tumor homing cells would improve treatment outcomes and guide the development of personalized therapies. Third, especially promising clinical direction is to selectively deliver anti-angiogenic, and therapeutic compounds as anticancer strategies. Because endogenous cells are utilized as natural biologic vectors, the barriers to commercialization and clinical implementation of our innovative diagnostic tracer are much lower than for other emerging technologies.

这个小型企业技术转移阶段I项目通过研究一个完全新颖的肿瘤靶向平台，采用了一种创新的肿瘤靶向方法，该平台利用骨髓衍生而来，将肿瘤归巢细胞作为天然载体。通过筛选噬菌体显示肽库，我们已经确定了具有高特异性结合这些细胞的高亲和肽配体。这些高亲和力，高特异性肽配体及其在肿瘤分子成像中的应用代表了该阶段I项目的创新。放射性标记的肽定向化合物将被合成，并提供分子有效载荷的潜力？在癌症小鼠模型中，专门针对恶性脉管系统。 The results from this development effort will provide proof-of-principle validation for a new targeting paradigm in which circulating tumor localizing cell populations can be exploited for highly transformative and innovative technology development for the benefit of cancer patients.The broader impact of this project and the commercialization of the molecular diagnostic tracer developed here will have important implications for furthering oncology care through personalized approaches: First, specific and sensitive imaging based on monitoring of homing of循环细胞向肿瘤组织有益于肿瘤分期和重新分期。 其次，此外，此开发工作的结果将提供与迄今为止缺乏治疗有关的更可预测的信息。通过监测或不存在循环肿瘤归巢细胞的存在或不存在会改善治疗结果并指导个性化疗法的发展，对患者对治疗的反应进行了密切评估。第三，尤其有希望的临床方向是选择性地提供抗血管生成和治疗化合物作为抗癌策略。由于内源细胞被用作天然生物学载体，因此我们创新的诊断示踪剂的商业化和临床实施的障碍要比其他新兴技术要低得多。